1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease - Pipeline Review, H1 2020, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Wilson Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 2, 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Wilson Disease - Overview
- Wilson Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Wilson Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Wilson Disease - Companies Involved in Therapeutics Development
- Alexion Pharmaceuticals Inc
- Aligen Therapeutics SL
- Deep Genomics Inc
- DepYmed Inc
- Generation Bio Co
- GMP-Orphan SA
- Krisani Bio Sciences Pvt Ltd
- LambdaGen Therapeutics
- Nobelpharma Co Ltd
- Ultragenyx Pharmaceutical Inc
- Vivet Therapeutics SAS
- Wilson Disease - Drug Profiles
- CM-1186 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DG-12P1 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DPM-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy for Wilson’s Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gene Therapy to Activate ATP7B for Wilson Disease - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KBHD-001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- methanobactin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tiomolibdate choline - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- trientine tetrahydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- UX-701 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- VTX-801 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- zinc acetate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Wilson Disease - Dormant Projects
- Wilson Disease - Product Development Milestones
- Featured News & Press Releases
- Apr 23, 2019: Vivet Therapeutics to present on its wilson disease drug candidate VTX-801 at 2019 American Society of Gene and Cell Therapy Annual Meeting
- Jun 27, 2018: Progress toward improved Wilson's disease drug
- Jun 01, 2018: Wilson Therapeutics to present data from WTX101 Phase 2 extension study at 4th Congress of the European Academy of Neurology
- Apr 12, 2018: Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
- Mar 28, 2018: Preliminary Long-Term Data For WTX101 In Wilson Disease Accepted As A Late-Breaker Presentation At EASL Annual Meeting
- Feb 16, 2018: First patient enrolled in pivotal Phase 3 FOCuS trial evaluating WTX101 for the treatment of Wilson Disease
- Dec 14, 2017: WTX101 Granted Fast Track Designation by the U.S. FDA for the Treatment of Wilson Disease
- Oct 23, 2017: Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease
- Oct 20, 2017: Promising Preliminary Long-term Data For WTX101 In Wilson Disease Highlighted at The Liver Meeting
- Oct 06, 2017: Phase 2 Clinical Trial Data for WTX101 Published in The Lancet Gastroenterology & Hepatology
- Oct 01, 2017: Promising Preliminary Long-term Data from WTX101 Phase 2 Extension Study to be Presented at AASLD Annual Meeting
- Sep 26, 2017: Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
- Jun 08, 2017: Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
- Apr 25, 2017: Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting
- Apr 24, 2017: Wilson Therapeutics presented positive final Phase 2 data for WTX101 at EASL Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Wilson Disease, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Wilson Disease - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
- Wilson Disease - Pipeline by Aligen Therapeutics SL, H1 2020
- Wilson Disease - Pipeline by Deep Genomics Inc, H1 2020
- Wilson Disease - Pipeline by DepYmed Inc, H1 2020
- Wilson Disease - Pipeline by Generation Bio Co, H1 2020
- Wilson Disease - Pipeline by GMP-Orphan SA, H1 2020
- Wilson Disease - Pipeline by Krisani Bio Sciences Pvt Ltd, H1 2020
- Wilson Disease - Pipeline by LambdaGen Therapeutics, H1 2020
- Wilson Disease - Pipeline by Nobelpharma Co Ltd, H1 2020
- Wilson Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2020
- Wilson Disease - Pipeline by Vivet Therapeutics SAS, H1 2020
- Wilson Disease - Dormant Projects, H1 2020
List of Figures
- Number of Products under Development for Wilson Disease, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals Inc
- Aligen Therapeutics SL
- Deep Genomics Inc
- DepYmed Inc
- Generation Bio Co
- GMP-Orphan SA
- Krisani Bio Sciences Pvt Ltd
- LambdaGen Therapeutics
- Nobelpharma Co Ltd
- Ultragenyx Pharmaceutical Inc
- Vivet Therapeutics SAS
